Cytokine release syndrome and immune effector cell‑associated neurotoxicity syndrome in a melanoma patient treated with adjuvant pembrolizumab

Ochenduszko,Sebastian; Landete,Lamberto; Martinez,David Collado; Feria,Ana García; Francés,Carla; Torregrosa,María Dolores; Maiques,Inmaculada Maestu

doi:10.3892/etm.2024.12712

Cytokine release syndrome and immune effector cell‑associated neurotoxicity syndrome in a melanoma patient treated with adjuvant pembrolizumab

Authors:
- Sebastian Ochenduszko
- Lamberto Landete
- David Collado Martinez
- Ana García Feria
- Carla Francés
- María Dolores Torregrosa
- Inmaculada Maestu Maiques
View Affiliations

Affiliations: Department of Oncology, Doctor Peset University Hospital, 46017 Valencia, Spain, Department of Neurology, Doctor Peset University Hospital, 46017 Valencia, Spain, Department of Oncology, University Hospital of La Ribera, 46600 Alzira, Spain, Department of Hematology, Doctor Peset University Hospital, 46017 Valencia, Spain, Department of Endocrinology, Doctor Peset University Hospital, 46017 Valencia, Spain
Published online on: September 11, 2024 https://doi.org/10.3892/etm.2024.12712
Article Number: 423

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The emergence of immune checkpoint inhibitors (ICIs) has significantly improved the prognosis of patients with solid tumors. However, along with their efficacy, new toxicities related to immune system activation have surfaced, some of which pose life‑threatening risks. Cytokine release syndrome (CRS) and immune effector cell‑associated neurotoxicity syndrome (ICANS) are among the serious, albeit rare, immune‑related adverse effects (irAEs) observed. Although commonly associated with hematologic malignancies and chimeric antigen receptor T cell therapies, CRS has been reported in patients treated with ICIs, with ICANS being a less documented complication. The present study presents a case report of a 76‑year‑old patient with resected melanoma who developed clinical symptoms of CRS and ICANS following adjuvant pembrolizumab therapy. The patient presented with neurological symptoms of weakness and encephalopathy with confusion, bradypsychia, dysarthria, tremors and visual hallucinations. Laboratory tests revealed elevated serum levels of tumor necrosis factor‑alpha and interleukin‑6 along with inflammatory markers, hepatic and renal dysfunction, as well as rapidly progressive normochromic‑normocytic anemia. Treatment with corticosteroids led to rapid symptom resolution, albeit with subsequent symptom recurrence after tapering its dose. This case underscores the importance of recognizing and managing irAEs associated with ICIs and highlights the need for vigilant monitoring and individualized therapeutic approaches.

View Figures

View References

1	Wesley SF, Haggiagi A, Thakur KT and De Jager PL: Neurological immunotoxicity from cancer treatment. Int J Mol Sci. 22(6716)2021.PubMed/NCBI View Article : Google Scholar
2	Ceschi A, Noseda R, Palin K and Verhamme K: Immune checkpoint inhibitor-related cytokine release Syndrome: Analysis of WHO global pharmacovigilance database. Front Pharmacol. 11(557)2020.PubMed/NCBI View Article : Google Scholar
3	Liu LL, Skribek M, Harmenberg U and Gerling M: Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint inhibitors: Case report and systematic review of the literature. J Immunother Cancer. 11(e005841)2023.PubMed/NCBI View Article : Google Scholar
4	Hamida O, Karlsson F, Lundqvist A, Gerling M and Liu LL: Cytokine release syndrome after treatment with immune checkpoint inhibitors: An observational cohort study of 2672 patients from Karolinska University Hospital in Sweden. Oncoimmunology. 13(2372875)2024.PubMed/NCBI View Article : Google Scholar
5	Tay SH, Toh MMX, Thian YL, Vellayappan BA, Fairhurst AM, Chan YH, Aminkeng F, Bharwani LD, Huang Y, Mak A and Wong ASC: Cytokine release syndrome in cancer patients receiving immune checkpoint inhibitors: A case series of 25 patients and review of the literature. Front Immunol. 13(807050)2022.PubMed/NCBI View Article : Google Scholar
6	Zhang Y, Wen X, OuYang Y, Hu Y, Fang X, Zhang J and Yuan Y: Severe cytokine release syndrome induced by immune checkpoint inhibitors in cancer patients-A case report and review of the literature. Heliyon. 10(e24380)2024.PubMed/NCBI View Article : Google Scholar
7	Tanaka T, Taoka M, Makimoto G, Ninomiya K, Higo H, Fujii M, Ichihara E, Ohashi K, Hotta K, Tabata M and Maeda Y: Severe cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome in a man receiving immune checkpoint inhibitors for lung cancer: A case report. Intern Med. 63:1261–1267. 2024.PubMed/NCBI View Article : Google Scholar
8	Kennedy LB and Salama AKS: A review of cancer immunotherapy toxicity. CA Cancer J Clin. 70:86–104. 2020.PubMed/NCBI View Article : Google Scholar
9	Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J and Jordan K: ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 28 (suppl_4):iv119–iv142. 2017.PubMed/NCBI View Article : Google Scholar
10	Puzanov I, Diab A, Abdallah K, Bingham CO III, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, et al: Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 5(95)2017.PubMed/NCBI View Article : Google Scholar
11	Tvedt THA, Vo AK, Bruserud Ø and Reikvam H: Cytokine release syndrome in the immunotherapy of hematological malignancies: The biology behind and possible clinical consequences. J Clin Med. 10(5190)2021.PubMed/NCBI View Article : Google Scholar
12	Wang J and Doran J: The many faces of cytokine release syndrome-related coagulopathy. Clin Hematol Int. 3:3–12. 2021.PubMed/NCBI View Article : Google Scholar
13	Morris EC, Neelapu SS, Giavridis T and Sadelain M: Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 22:85–96. 2022.PubMed/NCBI View Article : Google Scholar
14	Velasco R, Villagrán M, Jové M, Simó M, Vilariño N, Alemany M, Palmero R, Martínez-Villacampa MM, Nadal E and Bruna J: Encephalitis induced by immune checkpoint inhibitors: A systematic review. JAMA Neurol. 78:864–873. 2021.PubMed/NCBI View Article : Google Scholar
15	Siegler EL and Kenderian SS: Neurotoxicity and cytokine release syndrome after chimeric antigen receptor T cell therapy: Insights into mechanisms and novel therapies. Front Immunol. 11(1973)2020.PubMed/NCBI View Article : Google Scholar
16	Rice J, Nagle S, Randall J and Hinson HE: Chimeric antigen receptor T cell-related neurotoxicity: Mechanisms, clinical presentation, and approach to treatment. Curr Treat Options Neurol. 21(40)2019.PubMed/NCBI View Article : Google Scholar
17	Si S and Teachey DT: Spotlight on tocilizumab in the treatment of CAR-T-Cell-induced cytokine release syndrome: Clinical evidence to date. Ther Clin Risk Manag. 16:705–714. 2020.PubMed/NCBI View Article : Google Scholar
18	Ohira J, Kawamoto M, Sugino Y and Kohara N: A case report of fulminant cytokine release syndrome complicated by dermatomyositis after the combination therapy with immune checkpoint inhibitors. Medicine (Baltimore). 99(e19741)2020.PubMed/NCBI View Article : Google Scholar
19	Das S and Johnson DB: Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 7(306)2019.PubMed/NCBI View Article : Google Scholar